Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results
Apyx Medical (NASDAQ:APYX) has released preliminary revenue results for Q4 and full year 2024. The company expects Q4 total revenue between $14.1-14.3 million, down 3-4% year-over-year, with Advanced Energy revenue of $12.0-12.2 million (flat YoY) and OEM revenue of $2.1 million (down 17% YoY).
For full year 2024, total revenue is projected at $48.0-48.2 million, an 8% decrease YoY. Advanced Energy segment expects $38.5-38.7 million (down 11% YoY), while OEM revenue shows growth at $9.5 million (up 6% YoY).
Notable improvements include 25% quarter-over-quarter growth in Advanced Energy sales during Q4, doubled generator unit sales in H2 2024 compared to H1, and strong U.S. single-use handpiece sales. The company plans to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance, targeting the growing market for loose skin treatments, particularly driven by GLP-1 drug-related weight loss.
Apyx Medical (NASDAQ:APYX) ha rilasciato i risultati preliminari dei ricavi per il Q4 e l'intero anno 2024. L'azienda prevede un fatturato totale per il Q4 tra $14,1-14,3 milioni, in calo del 3-4% rispetto all'anno precedente, con ricavi da Advanced Energy di $12,0-12,2 milioni (stabili rispetto all'anno precedente) e ricavi OEM di $2,1 milioni (in calo del 17% YoY).
Per l'intero anno 2024, il fatturato totale è previsto intorno a $48,0-48,2 milioni, con una diminuzione dell'8% rispetto all'anno precedente. Il segmento Advanced Energy prevede ricavi di $38,5-38,7 milioni (in calo dell'11% YoY), mentre i ricavi OEM mostrano una crescita a $9,5 milioni (in aumento del 6% YoY).
Tra i miglioramenti notevoli si segnala una crescita del 25% trimestre su trimestre nelle vendite di Advanced Energy durante il Q4, un raddoppio delle vendite di unità generatore nella seconda metà del 2024 rispetto alla prima metà, e forti vendite di strumenti monouso negli Stati Uniti. L'azienda prevede di lanciare il nuovo Sistema di Contouring Corpopolitico AYON™ nella seconda metà del 2025, in attesa dell'approvazione della FDA, mirando al mercato in crescita per i trattamenti della pelle flaccida, particolarmente alimentati dalla perdita di peso legata ai farmaci GLP-1.
Apyx Medical (NASDAQ:APYX) ha publicado resultados preliminares de ingresos para el cuarto trimestre y el año completo 2024. La empresa espera que los ingresos totales del cuarto trimestre estén entre $14.1-14.3 millones, una disminución del 3-4% en comparación con el año anterior, con ingresos de Advanced Energy de $12.0-12.2 millones (estables en comparación con el año anterior) y ingresos OEM de $2.1 millones (disminución del 17% interanual).
Para el año completo 2024, se proyecta que los ingresos totales sean de $48.0-48.2 millones, lo que representa una disminución del 8% interanual. Se espera que el segmento de Advanced Energy genere entre $38.5-38.7 millones (una caída del 11% interanual), mientras que los ingresos OEM muestran un crecimiento de $9.5 millones (aumento del 6% interanual).
Mejoras notables incluyen un crecimiento del 25% trimestre a trimestre en las ventas de Advanced Energy durante el cuarto trimestre, ventas duplicadas de unidades generadoras en la segunda mitad de 2024 en comparación con la primera mitad, y fuertes ventas de instrumentos desechables en EE.UU. La empresa planea lanzar su nuevo Sistema de Contorno Corporal AYON™ en la segunda mitad de 2025, pendiente de la aprobación de la FDA, apuntando al creciente mercado de tratamientos para la piel flácida, impulsado especialmente por la pérdida de peso relacionada con los medicamentos GLP-1.
Apyx Medical (NASDAQ:APYX)는 2024년 4분기 및 전체 연도의 초기 수익 결과를 발표했습니다. 회사는 4분기 총 수익을 $14.1-14.3백만으로 예상하며, 이는 전년 대비 3-4% 감소한 수치입니다. Advanced Energy 부문의 수익은 $12.0-12.2백만 (전년 대비 보합)이고, OEM 수익은 $2.1백만 (전년 대비 17% 감소)입니다.
2024년 전체 연도의 총 수익은 $48.0-48.2백만으로 예상되며, 이는 전년 대비 8% 감소입니다. Advanced Energy 부문은 $38.5-38.7백만의 수익을 예상하고 있으며 (전년 대비 11% 감소), OEM 수익은 $9.5백만 (전년 대비 6% 증가)으로 성장이 나타났습니다.
특기할 만한 개선 사항으로는 4분기 동안 Advanced Energy 판매의 분기별 성장률이 25%라는 점, 2024년 하반기에는 상반기와 비교해 발전기 판매가 두 배로 증가한 점, 그리고 미국에서의 일회용 핸드피스 판매가 강세를 보이고 있습니다. 회사는 AYON™ 바디 윤곽 시스템을 2025년 하반기에 출시할 계획이며, FDA 승인 대기 중이며, GLP-1 약물 관련 체중 감소로 인한 느슨한 피부 치료 시장의 성장에 대응하고자 합니다.
Apyx Medical (NASDAQ:APYX) a publié des résultats préliminaires de revenus pour le quatrième trimestre et l'année complète 2024. La société prévoit un chiffre d'affaires total pour le quatrième trimestre compris entre $14,1-14,3 millions, soit une diminution de 3-4 % par rapport à l'année précédente, avec un revenu d'Advanced Energy de $12,0-12,2 millions (stable par rapport à l'année précédente) et un revenu OEM de $2,1 millions (en baisse de 17 % par rapport à l'année précédente).
Pour l'année complète 2024, le chiffre d'affaires total est projeté à $48,0-48,2 millions, soit une diminution de 8 % par rapport à l'année précédente. Le segment Advanced Energy espère un revenu de $38,5-38,7 millions (en baisse de 11 % par rapport à l'année précédente), tandis que le revenu OEM montre une croissance à $9,5 millions (en hausse de 6 % par rapport à l'année précédente).
Parmi les améliorations notables, on note une croissance de 25 % d'un trimestre à l'autre des ventes d'Advanced Energy au cours du quatrième trimestre, des ventes d'unités génératrices doublées dans la seconde moitié de 2024 par rapport à la première moitié, et de fortes ventes de mains-d'œuvre jetables aux États-Unis. L'entreprise prévoit de lancer son nouveau Système de Contour Corporel AYON™ au cours de la seconde moitié de 2025, sous réserve de l'approbation de la FDA, visant le marché en pleine expansion des traitements de la peau lâche, particulièrement stimulé par la perte de poids associée aux médicaments GLP-1.
Apyx Medical (NASDAQ:APYX) hat vorläufige Umsatzergebnisse für das 4. Quartal und das Gesamtjahr 2024 veröffentlicht. Das Unternehmen erwartet für das 4. Quartal einen Gesamtumsatz zwischen $14,1-14,3 Millionen, was einem Rückgang von 3-4% im Vergleich zum Vorjahr entspricht, mit einem Umsatz von Advanced Energy von $12,0-12,2 Millionen (stabil im Vergleich zum Vorjahr) und einem OEM-Umsatz von $2,1 Millionen (Rückgang von 17% im Vergleich zum Vorjahr).
Für das Gesamtjahr 2024 wird ein Gesamtumsatz von $48,0-48,2 Millionen prognostiziert, was einem Rückgang von 8% im Vergleich zum Vorjahr entspricht. Der Advanced Energy-Sektor erwartet einen Umsatz von $38,5-38,7 Millionen (Rückgang von 11% im Vergleich zum Vorjahr), während der OEM-Umsatz mit $9,5 Millionen ein Wachstum von 6% im Vergleich zum Vorjahr zeigt.
Bemerkenswerte Verbesserungen umfassen ein 25%iges Wachstum im Quartalsvergleich bei den Verkauf von Advanced Energy im 4. Quartal, verdoppelte Generatoreneinheitenverkäufe in der zweiten Hälfte von 2024 im Vergleich zur ersten Hälfte und starke Verkäufe von Einweg-Handstücken in den USA. Das Unternehmen plant die Einführung seines neuen AYON™ Body Contouring Systems in der zweiten Hälfte von 2025, vorbehaltlich der Genehmigung durch die FDA, um den wachsenden Markt für Behandlungen von schlaffer Haut zu bedienen, der besonders durch die Gewichtsreduktion im Zusammenhang mit GLP-1-Arzneimitteln vorangetrieben wird.
- Advanced Energy segment showed 25% quarter-over-quarter growth in Q4 2024
- Generator unit sales doubled in second half of 2024 compared to first half
- OEM revenue grew 6% year-over-year for full year 2024
- New AYON™ Body Contouring System planned for H2 2025 launch
- Total revenue declined 8% year-over-year for full year 2024
- Advanced Energy revenue decreased 11% year-over-year for full year 2024
- Q4 total revenue decreased 3-4% year-over-year
- Q4 OEM revenue declined 17% year-over-year
Insights
The preliminary Q4 2024 results reveal concerning trends for Apyx Medical. The 4% YoY decline in total revenue to
The sequential
The upcoming AYON™ Body Contouring System launch could be a catalyst, particularly given the growing market opportunity from GLP-1 weight loss drugs creating demand for skin tightening procedures. However, FDA clearance timing and market adoption remain uncertain variables.
The aesthetic device market dynamics reflected in these results highlight both challenges and opportunities. The doubling of generator unit sales in H2 2024 suggests improving capital equipment spending by medical practices, a key leading indicator for future consumables revenue. The strategic positioning of AYON™ to address post-GLP-1 weight loss skin laxity is particularly astute, as this represents an emerging high-growth market segment.
However, the
Advanced Energy revenue increase by more than
CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024.
Preliminary Fourth Quarter 2024 Revenue Summary:
- Total revenue expected to be in a range of approximately
$14.1 t o$14.3 million , representing a decrease of4% to3% year-over-year.- Advanced Energy revenue expected to be in a range of approximately
$12.0 t o$12.2 million , which is relatively flat year-over-year. - OEM revenue expected to be approximately
$2.1 million , representing a decrease of17% year-over-year.
- Advanced Energy revenue expected to be in a range of approximately
Preliminary Full Year 2024 Revenue Summary:
- Total revenue expected to be in a range of approximately
$48.0 t o$48.2 million , representing a decrease of8% year-over-year.- Advanced Energy revenue expected to be in a range of approximately
$38.5 t o$38.7 million , representing a decrease of11% year-over-year. - OEM revenue expected to be approximately
$9.5 million , representing growth of6% year-over-year.
- Advanced Energy revenue expected to be in a range of approximately
Management Comments:
“We are pleased with our financial performance in the fourth quarter of 2024, as we delivered over
This press release includes Apyx Medical Corporation’s preliminary revenue results for the quarter and year ended December 31, 2024. Apyx Medical plans to release its fourth quarter and full year 2024 results in March 2025. Actual fourth quarter and full year 2024 revenue results are subject to completion of the Company’s year-end financial closing procedures and year-end audit procedures by the Company’s independent registered public accounting firm.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
FAQ
What is APYX's expected total revenue for Q4 2024?
How much did APYX's Advanced Energy segment grow in Q4 2024?
What is APYX's projected full-year revenue for 2024?
When will APYX launch its new AYON Body Contouring System?
How did APYX's OEM revenue perform in 2024?
